Literature DB >> 25545205

Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format.

Magdalena Bialon1, Ludmila Schellenberg, Nicolas Herzog, Stefan Kraus, Hannah Jörißen, Rainer Fischer, Christoph Stein, Jörg Nähring, Stefan Barth, Christiane Püttmann.   

Abstract

Monoclonal antibodies are produced in cultured hybridoma cell lines, but these cells tend to be unstable; it is therefore necessary to rescue the corresponding genetic information. Here we describe an improved method for the amplification of antibody variable gene (V-gene) information from murine hybridoma cells using a panel of specific, non-degenerate primers. This primer set allows sequences to be rescued from all murine V-genes, except the lambda light chain genes, which rarely contribute to murine immune diversity. We tested the primers against a range of antibodies and recovered specific amplification products in all cases. The heavy and light chain variable regions were subsequently joined by a two-step cloning strategy or by splice overlap extension PCR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25545205      PMCID: PMC4278175          DOI: 10.1089/mab.2014.0044

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  27 in total

1.  Analysis of the expression immunoglobulin gene repertoire by screening libraries derived from PCR-amplified cDNA.

Authors:  K N Kasturi; C A Bona
Journal:  Nucleic Acids Res       Date:  1991-11-25       Impact factor: 16.971

2.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.

Authors:  H R Hoogenboom; A D Griffiths; K S Johnson; D J Chiswell; P Hudson; G Winter
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

3.  Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

Authors:  M B Khazaeli; M N Saleh; R H Wheeler; W J Huster; H Holden; R Carrano; A F LoBuglio
Journal:  J Natl Cancer Inst       Date:  1988-08-17       Impact factor: 13.506

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Medical applications of single-chain antibodies.

Authors:  J S Huston; J McCartney; M S Tai; C Mottola-Hartshorn; D Jin; F Warren; P Keck; H Oppermann
Journal:  Int Rev Immunol       Date:  1993       Impact factor: 5.311

6.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

Authors:  M Whitlow; B A Bell; S L Feng; D Filpula; K D Hardman; S L Hubert; M L Rollence; J F Wood; M E Schott; D E Milenic
Journal:  Protein Eng       Date:  1993-11

7.  Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.

Authors:  R E Hawkins; D Zhu; M Ovecka; G Winter; T J Hamblin; A Long; F K Stevenson
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

8.  Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6.

Authors:  J F Harris; R G Hawley; T S Hawley; G C Crawford-Sharpe
Journal:  J Immunol Methods       Date:  1992-04-08       Impact factor: 2.303

9.  Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections.

Authors:  L Duan; R J Pomerantz
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

10.  An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity.

Authors:  T T Wu; E A Kabat
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

View more
  2 in total

1.  Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.

Authors:  Diana Klose; Mira Woitok; Judith Niesen; Roger R Beerli; Ulf Grawunder; Rainer Fischer; Stefan Barth; Rolf Fendel; Thomas Nachreiner
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

2.  A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats.

Authors:  Francesco Nannini; Farhaan Parekh; Patrycja Wawrzyniecka; Leila Mekkaoui; Matteo Righi; Fatemeh V Dastjerdi; Jenny Yeung; Claire Roddie; Yuchen Bai; Biao Ma; Mathieu Ferrari; Shimobi Onuoha; Kerry Chester; Martin Pule
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.